The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Manipulating immune targeting of solid tumors with gene therapy
Akshat Jain, MD, MPH, FRCP, Loma Linda University, San Bernadino, CA, explores the application of gene editing in treating solid tumors, drawing inspiration from its success in managing sickle cell disease (SCD) and thalassemia. While not yet an established treatment for solid tumors, Dr Jain emphasizes the potential of manipulating immune cell genetic expression using tools like CRISPR/Cas9 to target tumor cells. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
